Sanaz Memarzadeh, MD, PhD
Antibody-directed therapies have shown potential with investigational targets such as mesothelin and folate receptor alpha, but researchers are actively exploring approaches that target the prevalent p53
, explained Sanaz Memarzadeh, MD, PhD.
function in the treatment of patients with ovarian cancer.
OncLive: What are some novel approaches that are being explored in ovarian cancer?
: Some of the research we are doing in our laboratory, in collaboration with investigators at UCLA, tie into one of these novel treatment options. The first approach is an immune-biologic approach with antibody-directed treatments. It utilizes the ability of an antibody to recognize an antigen expressed on a cancer cell. The antibody also carries a cytotoxic drug or a targeted drug that can be taken up by the cell. When the antibody binds to the antigen on the cell, it can go inside of the cell and directly target the cancer cell. What’s unique about this is the idea that it targets the cancer cell without targeting the normal cell. That is a major advantage of this approach.
... to read the full story